Invasive pneumococcal disease in Australia, 2002

Authors

  • Paul Roche Surveillance and Epidemiology Section, Department of Health and Ageing, GPO Box 9848 (MDP6), Canberra ACT 2601
  • Ross Andrews Communicable Diseases Section, Department of Human Services, Melbourne, Victoria
  • Vicki Krause Centre for Disease Control, Department of Health and Community Services, Darwin, Northern Territory
  • Louise Carter Communicable Diseases Control Unit, Department of Health and Community Care, Canberra, Australian Capital Territory
  • David Coleman Communicable Disease Surveillance, Department of Health and Human Services, Hobart, Tasmania
  • Heather Cook Centre for Disease Control, Department of Health and Community Services, Darwin, Northern Territory
  • Megan Counahan Communicable Diseases Section, Department of Human Services, Melbourne, Victoria
  • Carolien Giele Communicable Disease Control Branch, Department of Health, Perth, Western Australia
  • Robyn Gilmore Communicable Disease Control Branch, Department of Health, Perth, Western Australia
  • Sharon Hart Communicable Disease Control Branch, Department of Human Services, Adelaide, South Australia
  • Robyn Pugh Communicable Disease Unit, Queensland Health, Brisbane, Queensland
  • Geoff Hogg Microbiological Diagnostic Unit, University of Melbourne, Melbourne, Victoria
  • Denise Murphy Queensland Health Pathology and Scientific Services, Brisbane, Queensland
  • Michael Watson Department of Microbiology, Children's Hospital at Westmead, Westmead, New South Wales

DOI:

https://doi.org/10.33321/cdi.2003.27.75

Keywords:

disease surveillance, pneumococcal disease, polysaccharide pneumococcal vaccine, Streptococcus pneumoniae

Abstract

There were 2,271 cases of invasive pneumococcal disease (IPD) notified to the National Notifiable Diseases Surveillance System in Australia in 2002; a rate of 11.5 cases per 100,000 population. The notification rate varied between states and territories and by geographical region with the highest rates in the north of the country. Invasive pneumococcal disease was reported most frequently in children aged less than five years (57.3 per 100,000 population). Enhanced surveillance for IPD in 2002 was carried out in all states and territories, providing additional data on 1,929 (85%) of all notified cases. Rates of IPD in Indigenous Australians were 2.7 times the rate in non-Indigenous Australians. The clinical presentation of IPD was most commonly pneumonia (44%) and bacteraemia (35%). There were 175 deaths attributed to IPD resulting in an overall case fatality rate of 9.2 per cent. Forty-two per cent of all cases had a recognised risk factor for IPD. Seventy-five per cent of all pneumococcal isolates serotyped were serotypes in the seven-valent conjugate vaccine and 93 per cent were serotypes in the 23-valent polysaccharide pneumococcal vaccine. The clinical presentation and rates of risk factors varied between Indigenous and non-Indigenous cases and non-vaccine serotypes occurred more frequently among Indigenous children and adults. Commun Dis Intell 2003;27:465-476.

Downloads

Download data is not yet available.

References

Krause VL, Reid SJC, Merianos A. Invasive pneumococcal disease in the Northern Territory of Australia, 1994-1998. Med J Aust 2000;173:S27-S31.

O'Brien KL, Moulton LH, Reid R, Weatherholtz R, Oski J, Brown L, et al. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 2003;362:355-361.

Gilbert GL. Retreat of the pneumococcus? Med J Aust 2000;173 Suppl:S20-S21.

Turnidge J, Bell J, Collignon P. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Med J Aust 1999;170:152-155.

Douglas R, Miles H. Vaccination against Streptococcus pneumoniae in childhood: lack of demonstrable benefit in young Australian children. J Infect Dis 1984;149:861-869.

Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-195.

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-1746.

Fireman B, Black SB, Shinefield HR, Lee J, Lewis E, Ray P. Impact of the pneumococcal conjugate vaccine on otitis media. Paediatr Infect Dis J 2003;22:10-16.

Pelton S, Klein J. The future of pneumococcal conjugate vaccines for prevention of pneumococcal diseases in infants and children. Paediatrics 2002;110:805-814.

National Health and Medical Research Council. The Australian Immunisation Handbook. 7th edition. Canberra: Australian Government Publishing Services; 2000.

Andrews RM, Lester RA. Improving pneumococcal vaccination coverage among older people in Victoria. Med J Aust 2000;173 Suppl:S45-S47.

Roche P, McIntyre P, Spencer J. Pneumococcal disease in Australia: current status and future challenges. A report of the workshop held at the national Centre for Immunisation Research and Surveillance, 8-9 November 2002. Commun Dis Intell 2003;27:79-88.

Stewart D, Markey P. Review of the NT adult pneumococcal vaccine database. NT Disease Control Bulletin 2002;9:23-27.

Watson L, Wilson B, Waugh N. Pneumococcal polysaccharide vaccine: a systematic review of clinical effectiveness in adults. Vaccine 2002;20:2166-2173.

Mangtani P, Cutts F, Hall A. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence. Lancet Infect Dis 2003;3:71-78.

Jackson LA, Neuzil KM, Yu O, Benson P, Barlow WE, Adams AL, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003;348:1747-1755.

Benin AL, O'Brien KL, Watt JP, Reid R, Zell ER, Katz S, et al. Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J Infect Dis 2003;188:81-89.

Fedson DS. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence. Lancet Infect Dis 2003;3:272-273.

Artz A, Ershler WB, Longo DL. Pneumococcal vaccination and re-vaccination of older adults. Clin Micro Rev 2003;16:308-318.

Andrews R, Whitfield K, Kelly H, McIntyre P, Butler J. Economic analysis of various options for population level funded influenza and pneumococcal immunisation programs; 2002.

Dagan R. Antibiotic resistance and the potential impact of pneumococcal conjugate vaccines. Commun Dis Intell 2003;27 Suppl:S134-S142.

Downloads

Published

31/12/03

How to Cite

Roche, Paul, Ross Andrews, Vicki Krause, Louise Carter, David Coleman, Heather Cook, Megan Counahan, et al. 2003. “Invasive Pneumococcal Disease in Australia, 2002”. Communicable Diseases Intelligence 27 (December):465-76. https://doi.org/10.33321/cdi.2003.27.75.

Issue

Vol. 27 (2003)

Section

Annual report

Categories

License

Copyright (c) 2003 Communicable Diseases Intelligence

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>